Requip-Modutab 2 mg
Requip-Modutab 2 mg is a medicine authorised by Swissmedic under authorisation number 57740. The authorisation holder is GlaxoSmithKline AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 06 November 2007 and the authorisation is valid without a time limit. ATC code N04BC04 places the medicine in the group Anti-Parkinson drugs.
| Authorisation number | 57740 |
|---|---|
| Name | Requip-Modutab 2 mg |
| Full name | Requip-Modutab 2 mg, Tabletten mit veränderter Wirkstofffreisetzung |
| Authorisation holder | GlaxoSmithKline AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | N04BC04 |
| First authorisation | 06 November 2007 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Requip-Modutab 2 mg, Tabletten mit veränderter Wirkstofffreisetzung | B | 06 November 2007 |
| 3 | Requip-Modutab 4 mg, Tabletten mit veränderter Wirkstofffreisetzung | B | 06 November 2007 |
| 4 | Requip-Modutab 8 mg, Tabletten mit veränderter Wirkstofffreisetzung | B | 06 November 2007 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 3 | 28 | Tablette(n) | N04BC04 | 01.08.0. | B |
| 11 | 28 | Tablette(n) | N04BC04 | 01.08.0. | B |
| 15 | 28 | Tablette(n) | N04BC04 | 01.08.0. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Requip-Modutab 2 mg authorised in Switzerland?
Yes. Requip-Modutab 2 mg is authorised by Swissmedic under authorisation number 57740, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Requip-Modutab 2 mg have?
Requip-Modutab 2 mg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Requip-Modutab 2 mg?
The authorisation holder is GlaxoSmithKline AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.